ノバルティス(Novartis International AG)は、スイス・バーゼルに本拠地を置く、国際的な製薬・バイオテクノロジー企業である。スイス証券取引所、ニューヨーク証券取引所上場企業(SIX: NOVN、NYSE: NVS)。チバガイギー社(Ciba-Geigy)とサンド社(Sandoz)という、スイスを拠点とする製薬会社2社の合併によって1996年に設立されたwikipedia
DNA to stable cell line cell line : CHO, NS0, PER.C6, E.coli, Pichia identified in 19 weeks serum-free medium screening platform
Cell Banking
cGMP production facilities for MCB and WCB
Process Development
1) Upstream -1. process optimization, troubleshooting, media, feeding, process parameter – mammalian: flask, 2L, 5L, 50L SUB – microbial: 2L, 20L fermentor 2) Downstream -1. experience – mammalian: recombinant protein, fusion and mAb – microbial: inclusion body and soluble, pegylated protein, fusion and Plasmid DNA -2. equipment – LCS: AKTA PRIME, AKTA Pilot, AKTA Avant; column size: 1mL HiTrap to 14cmφBPG column – MF & UF system, UF/DF system,centrifuge of Disc and continuous, tank (316L SS), Homogenizer (Microfluidizer and APV) 3) Formulation -1. preformulation : Lyophilizer, Stability chamber, programmable controlled freezing and thawing system 4) Purity analysis – Three Agilent HPLC, one UPLC
Analytical/QC
– method development; method transfer; method qualification and validation; stability testing; Characterization : glycan analysis, glycan profile and ratio, monosaccharide, secondary or more analysis
– Item
– Potency/Activity : ELISA, Cell base assay – Impurity : Host cell DNA, Host cell protein, Protein A residue, Others – Biological safety : Endotoxin, Bioburden, Microbial enumeration – Analytical method qualification and validation : Specificity, Linearity & range, Accuracy and precision, LOD/LOQ – Glycan analysis : N and O-linked carbohydrates site and structure: HPLC/UPLC; N and O-linked glycan mapping and ratio : CE, LE/MS; N-glycan ratio : CE, LC/MS – Monosaccharide analysis : HPIC – Secondary and higher order structures: CD (Circular Dichroism), DSC (Differential Scanning Calorimetry), Fluorescence Spectrometer – Heterogeneity analysis : IEF/cIEF, CIX-HPLC
1st Floor : 10,000ft2 – Media preparation : 50L ~ 700L – 100L/500L SS – 50L/200L/1,000L SUB – Millipore POD and 3M CUNO filtration system – UF/DF (0.1~14 m2) – Column : 3mm ~ 10mmφ, 5cm~60cmφ – one purification room – one final purification room – Washer room and autoclave room – 2 x 2,000L SUB in northern part of Taiwan
GDP-fucose → ( Golgi apparatus or endoplasmic reticulum (ER) )
GDP-fucose transporter (GFT), encoded by the Slc35cl gene (Solute Carrier family 35), この遺伝子の変異は、白血球接着不全II型(LADII)、重度の免疫不全、精神遅滞、成長鈍化(グリコシル化IIc型の先天疾患)の発症につながります。
FcγRIIIaとの相互作用最大169倍 (S239D or I332E、S239D and I332E、S239D and I332E and A330L
「活性化FcγRIIIa」と「阻害性RcγRIIb」との結合比を最大9倍 (S239D and I332E and A330L): Xencorによるヒト化の抗CD19抗体(XmAb5574: 広範囲のBリンパ腫および白血病の細胞株に対するADCC活性増強、患者由来急性リンパ牙球性白血病とマントル細胞リンパ腫細胞のタイルADCC活性増強)
afucosilated 抗体の生産戦略
GDP-fucoseの生合成酵素
CHO Lec13細胞は、内因性(endogenous)のGDP-mannose 4, 6 – dehydratase (GMD) 遺伝子を欠乏しています。GMDは、de novo GDP-2 fucose生合成3経路 (biosynthesis pathway)の最初のステップの触媒を担っています。
Marketed first glycoengineered therapeutic anti-CD20, in 2013 by FDA 3 x Phase 1~3
mogamulizumab/POTELIGEO/KM0761 Kyowa Hakko Kirin
CD chemokine receptor 4(CCR4) Humanized afucosylated IgG1
Marketed in lymphoma first approved in 2013 in Japan for hematologic malignancies in 2014 for cutneous T-cell lymphoma (CTCL) in 2017, FDA granted itbreakthrough, FUT8-knockout CHO 10 x Phase1~3
Benralizumab/MDEI-563/Fasenra AstraZeneca
IL-5Rα Humanized afucosylated IgG1
Marketed in Asthma approved by FDA in 2017 for severe eosinophil asthma, FUT8-knockout CHO (Biowa Poteligent Technology), IL-5R 9 x Phase1~3
Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern, 2018